[Expert consensus on the diagnosis and treatment of allergic bronchopulmonary aspergillosis(2022 update)].

As an allergic lung disease caused by Aspergillus species, allergic bronchopulmonary aspergillosis(ABPA) is manifested by asthma and recurrent lung infiltrates, often with signs of bronchiectasis. ABPA is not uncommon, but under-diagnosis/misdiagnosis and inappropriate management are common in clinical practice, due to the varied manifestations, inconsistent diagnostic criteria, and the need of complicated laboratory studies. To improve the diagnosis and treatment of ABPA, experts of the Asthma Group of Chinese Thoracic Society proposed an expert consensus on the diagnosis and treatment of ABPA in 2017 (1 st Edition). Its publication has been well received by the Chinese physicians, and promoted the appropriate management of the disease. In the past 5 years, advances have been made in the investigation into the mechanisms, and in the diagnosis and therapy of ABPA, including novel insight into the pathogenesis, more studies of the diagnostic criteria, and more evidence on the efficacy of glucocorticoid, antifungal and/or biologic therapies. Based on new evidence and the clinical practice in China, experts of the Asthma Group of Chinese Thoracic Society updated the consensus.变应性支气管肺曲霉病（ABPA）是曲霉过敏引起的一种变应性肺部疾病，表现为支气管哮喘和反复出现的肺部阴影，可伴有支气管扩张。该病并不少见，但由于该病临床表现多样，诊断标准不一，且需要特殊的实验室检查，临床上存在诊断不及时、治疗不规范等情况。为了提高ABPA的诊断和治疗水平，推动相关领域的临床研究，中华医学会呼吸病学分会哮喘学组有关专家于2017年制定了《变应性支气管肺曲霉病诊治专家共识》。第一版共识发表后，引起了国内同行的关注，对于提高ABPA的诊治水平发挥了作用。近5年来有关ABPA的研究和诊治取得了一些新的认识和进展，包括对发病机制的新认识，对诊断标准的探讨，以及有关糖皮质激素、抗真菌药物和生物制剂治疗的研究证据；专家组在充分掌握上述新进展的基础上，结合我国的临床实践，对共识进行了修订。.